Syncom Formulations (India) Past Earnings Performance
Past criteria checks 5/6
Syncom Formulations (India) has been growing earnings at an average annual rate of 26.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 19.3% per year. Syncom Formulations (India)'s return on equity is 18.4%, and it has net margins of 15.6%.
How Syncom Formulations (India) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
NSEI:SYNCOMF Revenue, expenses and earnings (INR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
4,892
764
671
0
31 Dec 25
5,026
690
683
0
30 Sep 25
5,150
631
648
0
30 Jun 25
4,947
576
585
0
31 Mar 25
4,650
494
553
0
31 Dec 24
3,907
391
487
0
30 Sep 24
3,283
331
445
0
30 Jun 24
2,908
286
371
0
31 Mar 24
2,634
253
379
0
31 Dec 23
2,498
264
365
0
30 Sep 23
2,420
235
340
0
30 Jun 23
2,327
206
285
0
31 Mar 23
2,243
201
288
0
31 Dec 22
2,215
164
263
0
30 Sep 22
2,213
162
250
0
30 Jun 22
2,198
183
222
0
31 Mar 22
2,197
198
237
0
31 Dec 21
2,270
220
240
0
30 Sep 21
2,539
280
230
0
30 Jun 21
2,668
316
212
0
31 Mar 21
2,448
292
206
0
31 Dec 20
2,223
257
182
0
30 Sep 20
1,905
192
171
0
30 Jun 20
1,809
143
158
0
31 Mar 20
2,055
143
177
0
31 Dec 19
2,237
130
181
0
30 Sep 19
2,191
133
181
0
30 Jun 19
2,077
120
159
0
31 Mar 19
1,868
111
174
0
31 Dec 18
1,648
106
173
0
30 Sep 18
1,566
97
171
0
30 Jun 18
1,505
87
151
0
31 Mar 18
1,586
86
171
0
31 Mar 17
1,848
105
164
0
31 Mar 16
1,839
104
149
0
Quality Earnings: SYNCOMF has high quality earnings.
Growing Profit Margin: SYNCOMF's current net profit margins (15.6%) are higher than last year (10.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SYNCOMF's earnings have grown significantly by 26.6% per year over the past 5 years.
Accelerating Growth: SYNCOMF's earnings growth over the past year (54.6%) exceeds its 5-year average (26.6% per year).
Earnings vs Industry: SYNCOMF earnings growth over the past year (54.6%) exceeded the Pharmaceuticals industry 15.9%.
Return on Equity
High ROE: SYNCOMF's Return on Equity (18.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/08 18:24
End of Day Share Price
2026/07/08 00:00
Earnings
2026/03/31
Annual Earnings
2026/03/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syncom Formulations (India) Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.